Wayne R. Danter

aiAtlas v1.2 simulates genetic perturbations in virtual cell lines to identify phenotypic disruptions across rare diseases and cancers.

This paper evaluates the combination of Miglustat and Ambroxol in a virtual trial for Type 1 Tay-Sachs Disease using aiHumanoid simulations, showing improved outcomes at intermediate doses.

This study uses aiHumanoid simulations to show that LOF mutations in HNRNPH2 cause dominant-negative effects, leading to severe neurodevelopmental impairments and highlighting potential therapeutic strategies.

This study uses an aiHumanoids platform to simulate XPA disease progression, showing increased DNA damage, genomic instability, cancer risk, and neurological issues in XPA individuals under UV exposure.

This study uses aiHumanoid simulations to model how TEL-AML1 gene fusion and family history influence childhood ALL risk and progression.

This study uses AI simulations to examine how APOE genotypes influence Alzheimer's progression in virtual patients, identifying early biomarkers and disease patterns.

This study develops and validates an AI-based multi-organoid simulation called aiHumanoid to model gram-negative sepsis effects across multiple organ systems and evaluate its potential for drug discovery and personalized medicine.

The paper evaluates aiCRISPRL, an AI platform for simulating gene editing in stem cells and organoids, by comparing its capabilities to CRISPR-Cas9 using artificial HeLa cells.